

Lale Kostakoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/228871/publications.pdf>

Version: 2024-02-01

48
papers

2,978
citations

394421

19
h-index

243625

44
g-index

48
all docs

48
docs citations

48
times ranked

3822
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	1.6	1,269
2	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.	5.0	267
3	Efficacy and Safety of High-Specific-Activity ¹³¹ I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 623-630.	5.0	193
4	FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. <i>Cancer</i> , 2006, 107, 2678-2687.	4.1	165
5	The Impact of Positron Emission Tomography with ¹⁸ F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. <i>Journal of Urology</i> , 2019, 201, 322-331.	0.4	113
6	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	1.4	90
7	State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. <i>European Journal of Radiology</i> , 2014, 83, 2203-2223.	2.6	78
8	Metabolic Tumor Volume Metrics in Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 50-66.	4.6	75
9	A Phase II Study of ¹⁸ F-Fluorodeoxythymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1681-1689.	5.0	73
10	Current role of FDG PET/CT in lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1004-1027.	6.4	63
11	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	1.4	62
12	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	1.6	60
13	Brain and blood biomarkers of tauopathy and neuronal injury in humans and rats with neurobehavioral syndromes following blast exposure. <i>Molecular Psychiatry</i> , 2021, 26, 5940-5954.	7.9	56
14	Interim [¹⁸ F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. <i>Leukemia and Lymphoma</i> , 2012, 53, 2143-2150.	1.3	54
15	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200016.	5.8	37
16	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Blood</i> , 2014, 124, 3356-3364.	1.4	36
17	Reader Training for the Restaging of Biochemically Recurrent Prostate Cancer Using ¹⁸ F-Fluciclovine PET/CT. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1596-1602.	5.0	33
18	Feasibility and diagnostic performance of hybrid PET/MRI compared with PET/CT for gynecological malignancies: a prospective pilot study. <i>Abdominal Radiology</i> , 2018, 43, 3462-3467.	2.1	28

#	ARTICLE	IF	CITATIONS
19	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	5.2	21
20	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	3.5	21
21	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017, 130, 824-824.	1.4	21
22	Comparison of 11 automated PET segmentation methods in lymphoma. <i>Physics in Medicine and Biology</i> , 2020, 65, 235019.	3.0	19
23	PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma. <i>PET Clinics</i> , 2019, 14, 317-329.	3.0	16
24	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	5.2	16
25	Comparison of standardized uptake value ratio calculations in amyloid positron emission tomography brain imaging. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 21-26.	0.5	13
26	The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 135-143.	2.5	10
27	Comparison of PET/CT and PET/MR imaging and dosimetry of yttrium-90 (90Y) in patients with unresectable hepatic tumors who have received intra-arterial radioembolization therapy with 90Y microspheres. <i>EJNMMI Physics</i> , 2018, 5, 23.	2.7	9
28	Surveillance Imaging in HPV-related Oropharyngeal Cancer. <i>Anticancer Research</i> , 2018, 38, 1525-1529.	1.1	9
29	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	9
30	Optimization of yttrium-90 PET for simultaneous PET/MR imaging: A phantom study. <i>Medical Physics</i> , 2016, 43, 4768-4774.	3.0	8
31	End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma. <i>PET Clinics</i> , 2019, 14, 307-315.	3.0	8
32	Novel PET Radiotracers for Potential Use in Management of Lymphoma. <i>PET Clinics</i> , 2012, 7, 83-117.	3.0	7
33	Quantitative comparison of pre-therapy ^{99m} Tc-macroaggregated albumin SPECT/CT and post-therapy PET/MR studies of patients who have received intra-arterial radioembolization therapy with ⁹⁰ Y microspheres. <i>European Journal of Radiology</i> , 2018, 109, 57-61.	2.6	7
34	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. <i>EJHaem</i> , 2022, 3, 406-414.	1.0	6
35	PET-derived metabolic volume metrics in lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 331-341.	2.1	5
36	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Lymph nodes can accurately be measured on PET-CT for lymphoma staging/restaging without a concomitant contrast enhanced CT scan. <i>Leukemia and Lymphoma</i> , 2016, 57, 1083-1093.	1.3	3
38	Interim results of an open-label, single-arm trial of ultratrace I-131-iobenguane in patients with metastatic pheochromocytoma/paraganglioma (Pheo).. <i>Journal of Clinical Oncology</i> , 2012, 30, e13592-e13592.	1.6	3
39	Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1149-1154.	5.0	3
40	Updating the role of FDG PET/CT for evaluation of lung cancer manifesting in nonsolid nodules. <i>Clinical Imaging</i> , 2018, 52, 157-162.	1.5	2
41	Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 489-489.	1.4	2
42	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel ImidA® Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615.	1.4	1
43	Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials. <i>Blood</i> , 2018, 132, 1605-1605.	1.4	1
44	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019, 134, 883-883.	1.4	1
45	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	1.3	1
46	Guest Editorial. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 2-3.	4.6	0
47	A core laboratory approach to large-scale radiomics and machine-learning prediction of DLBCL outcomes after first-line treatment using results from the phase III GOYA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e19042-e19042.	1.6	0
48	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. <i>Blood</i> , 2019, 134, 4101-4101.	1.4	0